Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01329900 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01329900: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01329900 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01329900, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if it is possible to collect stem cells after ofatumumab and chemotherapy treatment. This study will also evaluate side-effects, number of stem cells collected, and the number of procedures that are needed to collect enough stem cells.
Interventions
- DRUG Mesna
- DRUG G-CSF
- DRUG Etoposide
- DRUG Ifosfamide
- DRUG Ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-08-22 |
| Est. Completion | 2019-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01329900
The ClinicalTrials.gov registry entry for NCT01329900 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Mesna is the first listed.
NCT01329900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01329900 about?
NCT01329900 is a clinical study titled "Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas". The goal of this clinical research study is to learn if it is possible to collect stem cells after ofatumumab and chemotherapy treatment. This study will also evaluate side-effects, number of stem cells collected, and the number of procedures that are needed to collect enough stem cells.
What is the current status of trial NCT01329900?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2011-08-22. Estimated completion is 2019-07-21.
What interventions are being tested in trial NCT01329900?
The interventions under investigation include: Mesna (DRUG), G-CSF (DRUG), Etoposide (DRUG), Ifosfamide (DRUG), Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT01329900?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.